Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chlamydia trachomatis is a Gram-negative, obligate intracellular bacterium and the causative agent of chlamydia, one of the most common sexually transmitted infections (STIs) worldwide. It is also responsible for trachoma, a leading infectious cause of blindness globally. The bacterium primarily infects mucosal epithelial cells in the genital tract, rectum, and conjunctiva. It exists in two forms: the infectious elementary body (EB) and the replicative reticulate body (RB). Infection triggers innate immune responses via TLRs and NOD-like receptors. Diagnosis relies on NAAT testing, and treatment involves antibiotics like tetracyclines or macrolides. There is currently no vaccine available.
Antibiotic; Inhibits bacterial protein synthesis or other essential bacterial functions
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chlamydia trachomatis (C. trachomatis).